Evidence map›Paper›PMID 40667673›Full record

Trial reportAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Baseline cognition and demographic, lifestyle, and cardiovascular risk factors in US POINTER.

Kathryn V Papp, Sarah Tomaszewski Farias, Marjorie Howard, Amber Thro, Tiia Ngandu, Brad Caudle, Bonnie C Sachs, Michelle Chan, Kristin R Krueger, Elizabeth R T Hartman and 13 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03688126 (U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03688126 nacompletednot on this map

U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk

TypeinterventionalSponsorWake Forest University Health SciencesRan2019 to 2025Enrolled2,000ConditionsAlzheimer DiseaseArmsSelf-Guided Lifestyle Intervention, Structured Lifestyle Intervention
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Elevated AD biomarkers do not explain cognitive performance in a community-recruited clinical trial cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Kathryn V PappDepartment of Neurology, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA.
Sarah Tomaszewski FariasDepartment of Neurology, University of California Davis, Sacramento, California, USA.
Marjorie HowardDepartment of Biostatistics and Data Science, Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Amber ThroDepartment of Neurology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Tiia NganduCenter for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institute, Stockholm, Sweden.
Brad CaudleDepartment of Neurology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Bonnie C SachsDepartment of Neurology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Michelle ChanDepartment of Neurology, University of California Davis, Sacramento, California, USA.
Kristin R KruegerDepartment of Internal Medicine, Rush Medical College, Chicago, Illinois, USA.
Elizabeth R T HartmanAdvocate Healthcare, Park Ridge, Illinois, USA.
Athene LeeDepartment of Psychiatry and Human Behavior, Brown University Alpert Medical School, Providence, Rhode Island, USA.
Michele K YorkDepartment of Neurology, Baylor College of Medicine, Houston, Texas, USA.
Marie T AustinDepartment of Neurology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Kathryn E DemosDepartment of Psychiatry and Human Behavior, Brown University Alpert Medical School, Providence, Rhode Island, USA.
Thomas M HollandDepartment of Internal Medicine, Rush Medical College, Chicago, Illinois, USA.
Xiaoyan LengDepartment of Biostatistics and Data Science, Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Rema RamanAlzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Heather M SnyderMedical and scientific relations, Alzheimer's Association, Chicago, Illinois, USA.
Maria C CarrilloMedical and scientific relations, Alzheimer's Association, Chicago, Illinois, USA.
Rachel A WhitmerDepartment of Public Health Sciences, University of California Davis, Davis, California, USA.
Mark A EspelandDepartment of Biostatistics and Data Science, Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Laura D BakerDepartment of Neurology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
US POINTER Study Group

Funding

Alzheimer's Association 19-611541
6 · The paper itself

Abstract

introductionValidation of the primary cognitive composite and baseline cognitive characteristics are presented for the US-Study-to-Protect-Brain-Health-Through-Lifestyle-Intervention-to-Reduce-Risk (US POINTER).

methodsUS POINTER is a multicenter, randomized clinical trial of two lifestyle interventions testing cognitive benefit in older adults without significant cognitive impairment but at-risk for decline due to well-established factors. Cognition is measured using a global cognitive composite (US POINTER modified Neuropsychological Test Battery-PmNTB).

resultsThe PmNTB is a valid cognitive composite, exhibiting good psychometric properties and tracking with other established outcomes. Among the 2111 enrolled participants (mean age = 68.2 years, 69% women, 31% from race and ethnic minoritized groups), demographic characteristics alone (age, sex, education, race, ethnicity) explained more variance in cognition measured using the PmNTB (25.94%) compared with cardiovascular and family history risk factors combined (added < 3% explained variance). DISCUSSION: In a large diverse older adult cohort, demographic features rather than well-established risks for cognitive decline correlate with baseline global cognition. CLINICAL TRIAL REGISTRATION NUMBER: NCT03688126 HIGHLIGHTS: Demographic characteristics explain baseline cognition in at-risk older adults. The POINTER Modified Neuropsychological Test Battery (PmNTB) is a valid measure. Worse cognition tracks with E4+, high HbA1c, current smoking, Framingham heart risk.

Indexed as

Cardiovascular DiseasesCognitionCognitive DysfunctionHeart Disease Risk FactorsLife StyleNeuropsychological TestsAgedFemaleHumansMaleMiddle AgedPsychometricsRisk FactorsUnited Statesclinical trialshealthy aginglifestyle interventionsrisk factors

Identifiers

PMID40667673
PMCPMC12265023

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.